SG Americas Securities LLC Has $531,000 Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

SG Americas Securities LLC raised its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 295.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,598 shares of the company’s stock after purchasing an additional 4,931 shares during the quarter. SG Americas Securities LLC’s holdings in PROCEPT BioRobotics were worth $531,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. KRS Capital Management LLC raised its position in shares of PROCEPT BioRobotics by 0.5% in the fourth quarter. KRS Capital Management LLC now owns 46,455 shares of the company’s stock valued at $3,741,000 after purchasing an additional 225 shares during the period. Essex Investment Management Co. LLC boosted its holdings in shares of PROCEPT BioRobotics by 0.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 80,992 shares of the company’s stock worth $6,489,000 after buying an additional 228 shares during the period. Values First Advisors Inc. acquired a new position in PROCEPT BioRobotics in the 3rd quarter valued at about $27,000. KBC Group NV raised its holdings in PROCEPT BioRobotics by 32.6% in the 3rd quarter. KBC Group NV now owns 1,531 shares of the company’s stock valued at $123,000 after acquiring an additional 376 shares during the period. Finally, Blue Trust Inc. lifted its position in PROCEPT BioRobotics by 11.7% during the third quarter. Blue Trust Inc. now owns 4,441 shares of the company’s stock worth $356,000 after acquiring an additional 466 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $75.00 target price on shares of PROCEPT BioRobotics in a research report on Tuesday, October 8th. Jefferies Financial Group assumed coverage on PROCEPT BioRobotics in a research report on Thursday, November 14th. They set a “hold” rating and a $95.00 price objective on the stock. Truist Financial reissued a “buy” rating and set a $105.00 target price (up previously from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Finally, Morgan Stanley initiated coverage on shares of PROCEPT BioRobotics in a report on Monday, December 2nd. They issued an “overweight” rating and a $105.00 price objective for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, PROCEPT BioRobotics presently has a consensus rating of “Moderate Buy” and an average price target of $97.86.

Insider Activity

In other news, CEO Reza Zadno sold 26,420 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $92.57, for a total transaction of $2,445,699.40. Following the completion of the transaction, the chief executive officer now owns 205,605 shares of the company’s stock, valued at approximately $19,032,854.85. The trade was a 11.39 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Antal Rohit Desai sold 33,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $96.60, for a total value of $3,187,800.00. Following the sale, the director now owns 231,363 shares of the company’s stock, valued at approximately $22,349,665.80. This represents a 12.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 174,355 shares of company stock worth $16,758,848. 17.40% of the stock is currently owned by corporate insiders.

PROCEPT BioRobotics Stock Up 1.3 %

PRCT stock opened at $72.50 on Friday. The company has a market cap of $3.78 billion, a PE ratio of -37.18 and a beta of 1.05. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a 52 week low of $45.20 and a 52 week high of $103.81. The business has a 50-day simple moving average of $84.45 and a 200 day simple moving average of $79.34.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).